secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMAC Holdings, Inc. (BACK)
CIK:        0001729944
Form:       8-K
Filed at:   2025-09-10T23:59:59+00:00
Accession:  0001641172-25-027034
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ignite Proteomics (BACK) enters $420K biomarker study with Inova for GI cancers
-------------------------------------------------------------------------------

- Subsidiary Ignite Proteomics will analyze up to 600 tumor samples using RPPA technology.
- Maximum contract value $420,000; $175,000 payable upon execution.
- Data on 32+ protein biomarkers including HER2, RET, MHC-II, EGFR, TROP2, AKT, ERK.
- Results provided to Inova's Molecular Tumor Board to guide late-stage gastrointestinal cancer therapy.
- Agreement expected to contribute meaningfully to Ignite's 2025 revenue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1729944/000164117225027034/0001641172-25-027034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1729944/000164117225027034/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-027034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer